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ABSTRACT
The currently known Mendelian colorectal cancer (CRC) predisposition syndromes 
account for ~5–10% of all CRC cases, and are caused by inherited germline mutations 
in single CRC predisposing genes. Using molecular inversion probes (MIPs), we 
designed a targeted next-generation sequencing panel to identify mutations in seven 
CRC predisposing genes: APC, MLH1, MSH2, MSH6, PMS2, MUTYH and NTHL1. From a 
consecutive series of 2,371 Chinese CRC patients, 140 familial and non-familial cases 
were selected that were diagnosed with CRC at or below the age of 35 years. Through 
MIP-based sequencing we identified pathogenic variants in six genes in 16 out of the 
140 (11.4%) patients selected. In 10 patients, known pathogenic mutations in APC 
(five patients), MLH1 (three patients), or MSH2 (two patients) were identified. Three 
additional patients were found to carry novel, likely pathogenic truncating (n = 2) and 
missense (n = 1) mutations in the MSH2 gene and a concomitant loss of expression of 
both the MSH2 and MSH6 proteins in their respective tumor tissues. From our data, we 
conclude that targeted MIP-based sequencing is a reliable and cost-efficient approach 
to identify patients with a Mendelian CRC syndrome.
INTRODUCTION
Colorectal cancer (CRC; MIM 114500) is the third 
most common cancer in males and the second in females 
worldwide, with 1.2 million patients diagnosed annually 
[1]. In China, CRC is the fifth most commonly diagnosed 
cancer and the fifth leading cause of cancer-related death 
among both men and women, with an estimated 376,300 
new patients and 191,000 deaths in 2015. Moreover, the 
age-standardized CRC incidence and mortality rates in 
China have shown a clear upward trend in recent years [2]. 
A family history of CRC or an early age at diagnosis are 
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indications for a genetic predisposition. Genetic factors 
are estimated to account for the development of ~30% 
of all CRCs [3]. The currently known Mendelian CRC 
predisposition syndromes, caused by germline mutations 
in single predisposing genes, account for ~5–10% 
of all CRCs [4]. Examples of autosomal dominant Mendelian 
CRC syndromes are Lynch syndrome (LS) caused by 
mutations in the mismatch repair (MMR) genes MLH1, 
MSH2, MSH6 or PMS2, familial adenomatous polyposis 
(FAP) caused by mutations in the APC gene and polymerase 
proofreading-associated polyposis (PPAP) caused by 
mutations in the exonuclease domain of the POLE or POLD1 
genes. Thus far, two autosomal recessive Mendelian CRC 
syndromes have been described, namely MUTYH-associated 
polyposis (MAP) caused by biallelic mutations in the MUTYH 
gene and NTHL1-associated polyposis caused by biallelic 
mutations in the NTHL1 gene [4–7]. A timely identification 
of individuals at a high risk to develop CRC allows pre-
symptomatic screening and genetic counseling, which may 
lead to reductions in both morbidity and mortality [8, 9].
In Western countries, CRC patients that are suspected 
of having a genetic predisposition for CRC are usually 
referred for genetic counseling to a clinical geneticist, who 
may advice for genetic testing. Until recently this testing was 
performed on a gene-by-gene basis, starting with the most 
likely candidate gene. With the advent of next-generation 
sequencing (NGS) technologies, however, it has become 
realistic to test a large panel of genes in a single assay, which 
is less laborious, less costly and less time-consuming [10]. 
Such an approach is also within reach now for centers and 
hospitals in which testing for a genetic cancer risk is not 
performed on a routine basis, as is the case in China. 
Here, we describe a targeted next-generation 
sequencing panel of molecular inversion probes (MIPs) 
to identify high-penetrance CRC predisposing mutations 
in early-onset or familial CRC patients from China. We 
designed customized MIPs for the coding regions of seven 
high-penetrance CRC susceptibility genes, i.e., APC, 
MLH1, MSH2, MSH6, PMS2, MUTYH and NTHL1 (POLE 
and POLD1 exonuclease domains were independently 
tested by Sanger sequencing), and evaluated the 
performance of these MIPs in the detection of genetically 
predisposed patients diagnosed before the age of 35.
RESULTS 
Patient cohort characteristics
An unselected series of 2,371 CRC patients aged 
between 15 and 93 years (median age 59 years old) was 
collected (Figure 1). The majority of these patients was 
aged 48–73 years. From this series, patients diagnosed at 
or before the age of 35 years (early-onset) were selected for 
the current study, i.e., 140 cases of which 84 (60%) were 
male (Figure 1). The median age of onset was 31 years 
[range 15–35 years]. The demographic and clinical features 
of this cohort of 140 cases are listed in Table 1.
Performance of the MIP sequencing panel
The MIP sequencing panel was designed to cover 
all coding exons and intron-exon boundaries (+/–20 bp) of 
seven selected CRC predisposing genes with double tiling. 
Sequence capture and library preparation was performed 
for all 140 samples, using unique barcodes per sample. 
After sequencing, 99.0% of the targeted regions of interest 
(ROIs) were covered at least 10-fold. The mean read depth 
was 4,055x [range 50x-15,770x] for APC, MLH1, MSH2, 
MSH6, PMS2 and MUTYH (‘six-gene’ panel) and 1,086x 
[range 63x-3,895x] for NTHL1. On average, 97.8% and 
83.3% of the ROIs were covered >100x for the six-gene 
panel and for NTHL1, respectively (Figure 2). Three ROIs 
were not covered or had an average coverage of <100x, 
i.e., exon 2 of APC (no reads), exon 1 of MSH6 (average 
coverage 92x) and exon 5 of NTHL1 (average coverage 
63x) (Figure 2). 
Identification of pathogenic germline variants in 
early-onset CRC cases
After a stringent filtering procedure (summarized in 
Figure 3), 30 candidate pathogenic variants were selected 
for further analysis. Of these 30 candidate variants, 17 
were confirmed by Sanger sequencing, whereas the 
other 13 with either a low sequencing depth (< 300x) 
or a low percentage of variant reads (< 20%) appeared 
to be false-positives (Supplementary Table 1). Among 
the 17 validated pathogenic variants (Figure 4), 13 were 
previously reported in the LOVD or ClinVar databases 
as pathogenic mutations underlying the respective 
hereditary CRC syndromes (Table 2). Five germline 
mutations were identified in the APC gene, including 
one nonsense mutation (c.694C>T, p.Arg232Ter) and 
four frameshift mutations (c.3202_3205delTCAA, 
p.Ser1068Glyfs*57 (n = 2), c.3807_3808delAT, 
p.Ile1269Metfs*6 and c.3885delA, p.Ala1296Glnfs*9). 
Two probands carried a monoallelic splice site mutation 
(c.934-2A>G, p.Glu313Serfs*8) in the MUTYH gene, 
which was previously reported as potentially pathogenic 
in Japanese and Korean CRC patients [11, 12]. In 
addition, we found two known nonsense (c.676C>T, 
p.Arg226Ter and c.887T>G, p.Leu296Ter) and two 
pathogenic missense (c.793C>T, p.Arg265Cys and 
c.1742C>T, p.Pro581Leu) mutations in the MLH1 gene, 
and a frameshift mutation (c.1457_1460delATGA, 
p.Asn486Thrfs*10) in the MSH2 gene in two probands 
(Table 2). The remaining four variants, detected in the 
MSH2 (n = 3) and MSH6 (n = 1) genes, were not found 
to be present in the dbSNP, ESP and ExAC databases 
and were, therefore, subjected to further analysis (see 
below). No pathogenic mutations were identified in the 
NTHL1 gene, and none of the genes was affected by 
germline copy number alterations using the CoNVaDING 
(Copy Number Variation Detection In Next-generation 
sequencing Gene panels) tool [13].
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Table 1: Demographic and clinical characteristics of the study subjects
Characteristic CRC diagnosed at ≤ 35 years CRC diagnosed at > 35 years
Total patients 140 (5.9) 2,231 (94.1)
Age
  Median age of onset (range) 31 (15–35) 60 (36–93)
  Mean age of onset 29.9 60.1
Gender
  Male (%) 84 (60.0) 1,312 (61.6)
  Female (%) 56 (40.0) 819 (38.4)
Diagnosis
  Colon adenoma (%)1 8 (5.7) 33 (1.5)
  Colon cancer (%)2 65 (46.4) 1,005 (45.1)
  Rectal adenoma (%)1 2 (1.4) 14 (0.6)
  Rectal cancer (%)2 65 (46.4) 1,179 (52.8)
1At least three adenomas detected; 2In the absence of (multiple) adenomas.
Figure 1: Age distribution histogram of the entire CRC patients series (n = 2,371). The frequency distribution per year-of-age 
in the entire CRC patient cohort is illustrated by blue bars, which show a normal distribution (red curve). The early-onset CRC patients 
enrolled for MIP-based sequencing are shown in the light gray square.
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Characterization of novel germline variants in 
early-onset CRC cases
Two novel truncating mutations and one 
novel missense mutation in the MSH2 gene 
(c.1062_1066delCAGAA, p.Ile356Glyfs*31, c.2557G>T, 
p.Glu853Ter and c.2039G>A, p.Arg680Gln) were 
identified in patients 13B-ON2505BD1 (male, rectal cancer 
at the age of 32 years), 13B-ON2469BD1 (male, sigmoid 
colon cancer at the age of 31 years) and B1287 (female, 
rectal cancer at the age of 30 years), respectively. One 
novel missense mutation in the MSH6 gene (c.3955A>C, 
p.Lys1319Gln) was identified in patient 14B-ON3654BD1 
(female, rectal cancer at the age of 34 years). Both missense 
variants were predicted to be pathogenic by the SIFT, 
Polyphen2 and CADD algorithms (Table 3). 
To assess whether the four novel MMR gene 
variants were indeed pathogenic, we performed 
immunohistochemistry (IHC) on the respective tumor 
tissues using antibodies directed against the MLH1, 
PMS2, MSH2 and MSH6 proteins. This analysis is based 
on the notion that a somatic second-hit mutation in the 
wild-type allele will result in loss of MLH1 and PMS2 
expression in MLH1-mutated cases, loss of both MSH2 
and MSH6 expression in MSH2-mutated cases and loss 
of MSH6 expression in MSH6-mutated cases [14, 15]. 
Formalin fixed paraffin embedded (FFPE) tissue blocks 
of seven cases were available for verification by IHC, 
including the four cases with novel mutations in the MSH2 
or MSH6 genes. In the tumors derived from patients B838 
and B1366, immunostaining was performed only for the 
MLH1 and MSH2 proteins. The remaining five patients’ 
tumor tissues were stained for all four MMR proteins 
(MLH1, MSH2, MSH6 and PMS2). Patients B838, B1366 
and 14B-ON3619BD1, who carried known pathogenic 
variants in the MLH1 gene, concordantly showed absence 
Figure 2: Mean read depth for each of the 99 exons targeted in the MIP panels. Box plots of mean read depth of the targeted 
exons with boxes representing ±25% and whiskers depicting the 5–95% percentiles (Y-axis: fold coverage, x-axis: exons included for 
targeted sequencing). Mean read depth per exon of MLH1 (A), MSH2 (B), MSH6 (C), PMS2 (D), APC (E), MUTYH (F), and NTHL1 (G).
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of MLH1 nuclear staining in their tumors. The tumor tissue 
from patient 14B-ON3619BD1 also showed a negative 
IHC staining for PMS2 (Table 4, Supplementary Figure 1). 
The three cases with novel mutations in the MSH2 gene 
(13B-ON2505BD1, B1287 and 13B-ON2469BD1) all 
showed loss of expression of both the MSH2 and MSH6 
proteins in their tumor tissues, which strongly suggests 
that these variants are indeed pathogenic. In patient 
14B-ON3654BD1, carrying a novel missense variant in 
the MSH6 gene, a normal expression of all MMR proteins 
was observed in the tumor tissue, indicating that this 
mutation may not be pathogenic (Table 4, Figure 5).
Contribution of known and novel germline 
pathogenic mutations 
Taken together, we identified pathogenic or likely 
pathogenic germline mutations in 16 of the 140 patients 
tested, and firmly established a diagnosis in 14 patients 
(10%) (Figure 6). The most frequently diagnosed 
syndrome was Lynch Syndrome (9 cases; 6.4%). Four 
patients (2.9%) carried a mutation in the MLH1 gene 
and five patients (3.6%) carried a mutation in the MSH2 
gene. FAP, caused by mutations in APC, was diagnosed 
in 3.6% (5 cases) of the patients. Two patients carried a 
monoallelic mutation in the MUTYH gene, but mutations 
in the remaining allele, which would be indicative for the 
diagnosis of MAP, were not detected.
DISCUSSION
A targeted next-generation sequencing panel 
using molecular inversion probes (MIPs) was developed 
to identify high-penetrance mutations in the CRC 
predisposing genes APC, MLH1, MSH2, MSH6, PMS2, 
MUTYH and NTHL1. We applied this panel to a cohort 
of 140 early-onset Chinese CRC patients (diagnosed 
at or below the age of 35 years). Using this approach, 
we identified known pathogenic mutations in 13 cases, 
and in three additional cases novel, likely pathogenic, 
Figure 3: Schematic chart showing the stepwise strategy for the detection of pathogenic mutations. Dashed arrows 
represent exclusion criteria. Germline variants known to be associated with hereditary CRC syndromes were initially selected and searched 
for evidence of pathogenicity in relevant databases, i.e., InSiGHT (http://www.insight-group.org/), LOVD (https://atlas.cmm.ki.se/
LOVDv.2.0/), the Mismatch Repair Genes Variant Database (http://www.med.mun.ca/mmrvariants/) and Clinvar (http://www.ncbi.nlm.
nih.gov/clinvar/). Next to the identification of known pathogenic variants, we searched for novel potential pathogenic rare variants (For 
details see Materials and Methods section).
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mutations in the MSH2 gene were found with confirmed 
loss of MSH2 protein expression in the tumors. Two of 
the 13 patients were found to carry a known pathogenic 
monoallelic MUTYH mutation, of which the clinical 
relevance remains inconclusive at this point. Therefore, a 
firm diagnosis could be made in 14 cases (10%).
The diagnosis hereditary CRC mainly relies on 
clinico-pathological features, family history and genetic 
data. Although international criteria for hereditary CRC 
have been defined, such as the Amsterdam criteria I and II, 
the Bethesda guidelines and the Japanese standards, they 
are not suitable for small pedigrees, which are common 
in China. Furthermore, the characteristics of hereditary 
CRC cases in the Chinese population may differ from 
those in Western countries [16]. As of yet, genetic testing 
for hereditary CRC is not performed on a routine basis 
in China. The recent development and implementation of 
next-generation sequencing technologies makes rapid and 
cost-effective genome sequencing feasible. Particularly, 
targeted sequencing approaches are highly suitable for 
implementation in routine diagnostic testing of patients 
with a suspected (colorectal) cancer syndrome. Here, 
we used MIP-based sequencing, a recently developed 
approach that has successfully been applied to targeted 
DNA sequencing of clinical samples [17, 18]. MIPs 
provide a high target sensitivity (99%) and specificity 
(98%) at low costs and minimal DNA requirements, and 
can be easily multiplexed to target regions of multiple 
genes in a single reaction [18]. Implementation of this 
methodology in routine diagnostics requires further 
adjustments to guarantee minimal costs and optimal 
turnaround times, which are highly dependent on sample 
supply, available infrastructure, and local personnel costs 
[19, 20]. For a MIP-based breast cancer susceptibility gene 
panel, a turnaround time of 4 days has been described 
[19]. Therefore, we consider MIP-based sequencing as 
a highly suitable replacement of Sanger sequencing for 
clinical genetic testing [17]. 
Table 3: Novel germline variants in known CRC predisposing genes
Table 2: Known germline pathogenic variants in CRC predisposing genes for early-onset CRC
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We found that with our newly designed MIP 
sequencing panel 99% of the target regions of interest 
(ROIs) were covered at least 10x. The majority (97%, 
96/99) of the target ROIs was covered more than 100x 
(ranging from 186x to 15,770x), whereas exon 2 of APC, 
exon 5 of NTHL1 and exons 1 of MSH6 showed poor 
coverages. For APC, no pathogenic or likely pathogenic 
mutations in exon 2 associated with CRC or FAP have 
been reported in the LOVD [21]. Exon 5 of NTHL1 
showed a mean coverage of 63x and exon 1 of MSH6 
showed a mean coverage of 92x. Further probe rebalancing 
and supplementation may improve the capture uniformity 
from probe to probe and the coverage of the poorly 
captured regions. For the candidate pathogenic variants, 
Sanger sequencing-based validation revealed that 17 
variants with a good coverage (> 600x) and a high mutant 
allele frequency (≥ 25%) could readily be confirmed, 
while the other 13 discrepant variants with a relatively 
low sequencing depth (< 300x) or a low variant allele 
frequency (< 20%) could not be confirmed (Supplementary 
Table 1), suggesting that further optimization of the 
thresholds for read depth and variant allele frequency will 
lower the number of false positives. The use of a higher 
thresholds for variant calling may decrease the chance to 
detect patients with (rarely occurring) germline mutations 
that are present in a low-mosaic state [22]. To overcome this 
limitation, we recently applied single-molecule molecular 
inversion probes (smMIPs) to FFPE tissue-derived DNA, 
which performs molecular tagging of DNA molecules, and 
gives reliable results [20]. 
Of note, among the 17 confirmed mutations 
identified, 13 (76.5%) were previously reported to be 
associated with hereditary CRC syndromes in public 
databases such as InSiGHT, LOVD and the Mismatch 
Repair Genes Variant database. Three novel mutations in 
the MSH2 gene were considered to be likely pathogenic, 
whereas one novel missense variant in the MSH6 gene 
may not be pathogenic based on our IHC staining results. 
Together, these pathogenic and likely pathogenic germline 
mutations explain 10% of the early-onset CRC patients 
included in our cohort. Some of the remaining 90% of 
the patients in our cohort may carry germline mutations 
in known genes that are not included in our panel yet, 
such as SMAD4/BMPR1A, POLE or POLD1, or in genes 
that still await discovery. However, it is likely that the 
majority of these cases does not carry a mutation in a high-
penetrant gene. Lower penetrance genetic factors and/or 
environmental factors may have caused the early onset 
of colorectal cancer in these cases, as has recently been 
proposed [23]. 
With five pathogenic germline mutations in five 
patients, APC is the most frequently mutated CRC 
predisposition gene in our cohort. Indeed, from four of 
these patients a polyposis phenotype (> 100 colonic 
polyps) had indeed been recorded. With mutations 
detected in 6 MMR genes, Lynch Syndrome is the most 
prevalent CRC syndrome encountered in our cohort, 
which is in agreement with a previous study using whole 
exome sequencing of Chinese early-onset and familial 
CRC patients [24] and with the studies of Tanskanen 
et al. [25] and Chubb et al. [23]. Others have reported 
various frequencies of germline MMR gene mutations in 
selected CRC cohorts with a broad range in estimates of 
their contributions to CRC development [26]. MSH2 was 
found to be the most frequently mutated MMR gene in our 
cohort, which is consistent with other studies in southern 
Chinese CRC patients reported by Liu et al. [27], Yang et 
al. [28] and Jin et al. [29]. However, this frequency differs 
Table 4: Immunohistochemical expression of DNA MMR proteins in tumor tissue of patients 
carrying MMR gene mutations
Gene Proband Gene Protein change
Tumor expression of MMR proteins
MLH1 PMS2 MSH2 MSH6
Known germline pathogenic 
mutations
H38 MLH1 p.Arg226Ter N/A N/A N/A N/A
B838 MLH1 p.Arg265Cys – N/A + N/A
B1366 MLH1 p.Leu296Ter – N/A + N/A
14B-ON3619BD1 MLH1 p.Pro581Leu – – + +
12B-ON1922BD1 MSH2 p.Asn486Thrfs*10 N/A N/A N/A N/A
12B-ON2092BD1 MSH2 p.Asn486Thrfs*10 N/A N/A N/A N/A
Rare and novel germline 
pathogenic mutations
13B-ON2505BD1 MSH2 p.Ile356Glyfs*31 + + – –
B1287 MSH2 p.Arg680Gln + + – –
13B-ON2469BD1 MSH2 p.Glu853Ter + + – –
14B-ON3654BD1 MSH6 p.Lys1319Gln + + + +
N/A: Not available.
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Figure 4: Protein alterations resulting from the mutations in known CRC predisposing genes identified in the studied 
cohort. The alterations are shown for APC (A), MLH1 (B), MSH2 (C), MSH6 (D) and MUTYH (E). Alterations shown in blue represent 
newly identified pathogenic mutations in this study; black entries denote previously reported pathogenic mutations in hereditary CRC 
syndromes. No loss of MSH6 protein expression was observed in the tumor of patient 14B-ON3654BD1, carrying the MSH6 missense 
variant p.Lys1319Gln.
Oncotarget24541www.impactjournals.com/oncotarget
Figure 5: IHC staining of MMR proteins in tumor tissue of four patients carrying rare and novel germline mutations. 
Loss of nuclear expression of the MSH2 and MSH6 proteins and normal expression of the MLH1 and PMS2 proteins in tumor tissues 
were observed in (A) patient 13B-ON2505BD1, with the MSH2 p.Ile356Glyfs*31 frameshift mutation, (B) patient B1287, with the MSH2 
missense mutation p.Arg680Gln and (C) patient 13B-ON2469BD1, with the MSH2 nonsense mutation p.Glu853Ter. Normal staining of 
the MLH1, PMS2, MSH2 and MSH6 proteins was observed in (D) tumor tissue of patient 14B-ON3654BD1, with the MSH6 missense 
mutation p.Lys1319Gln. (100x magnification).
Figure 6: Contribution of known and novel germline pathogenic mutations to early-onset colorectal cancer in Chinese 
patients. *In both MUTYH mutated patients (13B-ON3015BD1 and 13B-ON2469BD1, unrelated) only monoallelic mutations (c.934-
2A>G; p.Glu313SerfsX8) were detected; FAP: familial adenomatous polyposis; LS: lynch syndrome. 
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from other studies reporting that the MLH1 gene was more 
frequently affected than the MSH2 gene [24, 30–32]. More 
studies are, however, required to exactly determine the 
MLH1 and MSH2 mutation rates in different regions and 
ethnicities in China.
We identified in two unrelated patients a 
monoallelic MUTYH splice site variant (c.934-2A>G, p. 
Glu313SerfsX8), which has been reported to be probably 
pathogenic in Japanese and Korean CRC patients [11, 
12]. Although no mutations were identified on the second 
MUTYH allele in these two individuals, it is still possible 
that pathogenic germline mutations are present on this 
allele outside the detection range of our MIP sequencing 
panel (i.e., introns or promoter). Sequencing of tumor-
derived DNA of these patients may additionally reveal 
whether the somatic mutations present are biased towards 
G>A transversions, which is a typical feature of MAP-
associated tumors [33].
In summary, we developed a MIP-based next-
generation sequencing panel that targets the coding exons 
and flanking exon-intron boundaries (+/–20 bp) of seven 
high-penetrant CRC predisposing genes. Our data indicate 
that targeted MIP-based sequencing is a reliable approach 
for the identification of Chinese early-onset CRC patients 
with a Mendelian syndrome. This approach is cost- and 
time-efficient compared to Sanger sequencing [18]. For 
the specific purpose of molecular diagnostics, this strategy 
shows advantages over phenotype-based gene-specific 
testing. Since the international standards on hereditary 
CRC are not applicable to small families as commonly 
seen in China, such a sequencing-based strategy may be 
particularly beneficial for the Chinese population.
MATERIALS AND METHODS
Study subjects 
Whole blood from 2,391 patients with CRC was 
collected between 2007 and 2014 by the Sixth Affiliated 
Hospital, Sun Yat-sen University, Guangzhou, China. 
Probands with an age at diagnosis of ≤ 35 years, with or 
without a family history for CRC, were selected. For the 
current study 140 early-onsets CRC cases were included 
of whom DNA was available for testing. All included 
patients provided informed consent. This study was 
reviewed and approved by the Institutional Review Board 
of the Sixth Affiliated Hospital, Sun Yat-sen University, 
Guangzhou, China.
Genomic DNA isolation 
Genomic DNA was extracted from peripheral blood 
cells using a Gentra Puregene Blood Kit (QIAGEN, 
Hilden, Germany) according to the protocol provided 
by the manufacturer. The DNA was quantified using a 
NanoDrop 2000 UV-Vis Spectrophotometer (Thermo 
Scientific) and the DNA concentration was normalized to 
25 ng/µl for MIP-based sequencing. 
Molecular inversion probe (MIP) design, capture 
and sequencing
For six genes included in the targeted sequencing 
effort in this study, i.e., APC, MLH1, MSH2, MSH6, 
PMS2 and MUTYH, 626 MIPs were designed. In 
addition, 23 MIPs targeting the last exon of EPCAM, a 
gene located ~25 kb upstream of MSH2, were included 
to allow detection of deletions of the 3′ end of EPCAM, 
which leads to in cis inactivation of the MSH2 promoter 
[34] (Supplementary Figure 2). For the NTHL1 gene we 
generated another multiplex panel of 23 MIPs (Table 5). 
These MIPs were designed as described previously [35], 
targeting the coding exons and flanking exon-intron 
boundaries (+/–20 bp) of the respective genes, in total 
covering 22,834 of the 23,062 (99.01%) coding base pairs. 
Except for NTHL1, all targeted regions had a double tiling. 
Targeted capture with MIPs was performed as previously 
reported [18, 36], with some slight modifications [7]. 
In brief, a total of 100 ng of genomic DNA was used to 
capture the target regions in a mixture of 25 µl containing 
4.38E-05 picomoles 5′-phosphorylated MIPs in Ampligase 
DNA Ligase Buffer (Epicentre, Madison, WI, USA), 0. 
32 µM  dNTPs (NEB, Ipswich, MA, USA), 3.2 U Hemo 
Klentaq (NEB, Ipswich, MA, USA), and 1 U Ampligase 
100 U/ul (Epicentre, Madison, WI, USA). After 
denaturation (95°C) for 10 minutes and incubation (60°C) 
for 22 hours, linear probes and the remaining genomic 
DNA were removed by exonuclease treatment. Next, the 
captured material was amplified by PCR using barcoded 
reverse primers. The resulting PCR products were pooled 
and combined (140 samples) into a library. The resulting 
libraries (from the two multiplex panels) were sequenced 
using an Illumina NextSeq500 system, with 2 × 150-bp 
paired-end reads.
Data analysis and variant calling
Barcode-specific FASTQ files were mapped 
and annotated for APC (NM_001127510.2), MLH1 
(NM_000249.2), MSH2 (NM_000251.2), MSH6 
(NM_000179.2), PMS2 (NM_000535.5), MUTYH 
(NM_001128425.1) and NTHL1 (NM_002528.5), and 
variants were called using SeqNext (JSI Medical Systems; 
version 4.2.0). Subsequently, we selected all variants not 
found in our in-house database (5,036 in-house analyzed 
exomes, without suspected cancer predisposition, mostly 
from European ancestry), and with a MAF < 0.001 in 
dbSNPv142, Exome Variant Server, NHLBI GO Exome 
Sequencing Project (ESP), Seattle, WA (6,503 exomes, 
URL: http://evs.gs.washington.edu/EVS/) and Exome 
Aggregation Consortium (ExAC), Cambridge, MA 
(60,706 unrelated exomes, http://exac.broadinstitute.org). 
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To exclude false-positive calls due to technical artifacts, 
the following variant calls were excluded: less than 100-
fold absolute coverage, less than 10% variant reads and 
less than 30 variant reads. Furthermore, all unknown 
variants that were called in > 10% of the samples were 
considered as local normal variation and were also 
excluded. 
Delineation of pathogenic mutations
A stepwise strategy was used to systematically 
identify putative pathogenic mutations. We initially 
selected germline variants known to be associated with 
hereditary CRC syndromes and searched for evidence of 
pathogenicity in relevant databases, i.e., InSiGHT (http://
www.insight-group.org/), LOVD (https://atlas.cmm.
ki.se/LOVDv.2.0/), the Mismatch Repair Genes Variant 
Database (http://www.mmruv.info/) and ClinVar (http://
www.ncbi.nlm.nih.gov/clinvar/). Next to the identification 
of known pathogenic variants, we searched for novel 
potential pathogenic rare variants using the integrated 
mutation prediction software Alamut Visual version 2.5 
(Interactive Biosoftware, Rouen, France). For the selection 
of these variants, at least one of the following criteria 
should be met: (i) variants that result in truncation of 
the protein, including nonsense and frameshift variants, 
and variants predicted to cause splice site defects; (ii) 
non-synonymous missense variants at highly conserved 
nucleotide positions (phyloP ≥ 3.0) [37], which score 
“deleterious” by both SIFT [38] and PolyPhen2 [39]; (iii) 
variants with CADD scores > 15 as scored by Combined 
Annotation-Dependent Depletion (CADD) [40], which is a 
method for objectively integrating diverse annotations into 
a single measure (C score) for each variant.
Variant validation by sanger sequencing
The identified potentially pathogenic germline 
variants were validated by Sanger sequencing after PCR 
amplification. The PCR primers were designed using 
the Primer3 software package [41] (primer sequences 
available upon request). The PCR reactions were 
performed using a Dual 96-Well GeneAmp PCR System 
9700 (Applied Biosystems) using standard protocols. 
Mutation analyses were performed using the Vector NTI 
software package (Invitrogen, Paisley, UK).
Immunohistochemical detection of MMR 
proteins
Expression of the MMR proteins MLH1, MSH2, 
MSH6 and PMS2 was assessed by immunohistochemistry 
(IHC) on 4-µm sections of formalin fixed paraffin 
embedded (FFPE) tissue samples containing tumor 
Table 5: Summary of 7 high-penetrance CRC genes in the MIP panel
Gene Gene Acession Number
# of 
Exons
# of 
Coding 
Bases
# of 
Targeted 
Coding 
Bases
# of 
MIPs
Associtated 
Syndromesc
Associated Cancersd
(Lifetime risk (%) or fold-
increase in risk)
NCCN 
Guidelines 
[48]
References
APC NM_001127510.2 17 8725 8618 201
Familial 
Adenomatous 
Polyposis (FAP)/
Attenuated FAP 
(AFAP)
Colorectal (70% for AFAP, 
100% for FAP), Duodenum/
periampullary (4–12%), Thyroid 
(1–2%), Hepatoblastoma (1–2), 
Pancreas (2%), Medulloblastoma 
(< 1%), Gastric (< 1%)
Y [48–51]
MLH1 NM_000249.2 19 2271 2218 86
Lynch Syndrome
Colorectal (15–82%), Endometrial 
(15–60%), Gastric (11–19%), 
Ovarian (9–12%),  Small intestine, 
Hepatobiliary, Upper urinary tract, 
CNS, Sebaceous gland
Y  [52–57]
MSH2a NM_000251.2 16 2805 2750 112
MSH6 NM_000179.2 10 4083 4070 101
PMS2 NM_000535.5 15 2589 2589 84
MUTYH NM_001128425.1 16 1650 1650 65 MUTYH-associated Polyposis (MAP)
Colorectal (80%),  Breast cancer 
(females), Duodenum (4%), 
Gastric, Endometrial
Y  [58–61]
NTHL1b NM_002528.5 6 939 939 23 NTHL1-associated Polyposis Colorectal and Endometrial N  [7]
Total 99 23062 22834 672     
a Targeted capture region includes coding sequence of MSH2 and 25 kb upstream of MSH2, which harbors deletion of the 3′ end of EPCAM leading to 
inactivation of the MSH2 promoter.
b Involved in another independent panel which includes 4 DNA glycosylase genes NTHL1, OGG1, MPG and SMUG1. 
c Syndromes are associated with biallelic mutations in the genes listed. With the exception of MUTYH, associated cancers specified in this table are for 
monoallelic mutation carriers. 
d Cancer risks are not yet well-defined for all cancers associated with these genes to date. If known, cancer risks are expressed by lifetime cancer risk.
Gene name, number of exons, size, number of coding bases for which probes were successfully designed, and number of probes for targeted capture of the 
coding sequence of 7 genes harboring clinically actionable mutations.
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tissue and adjacent normal mucosa. IHC staining was 
performed using a BenchMark XT automated tissue 
staining system (Ventana Medical Systems, Inc., Tucson, 
AZ, USA), according to validated protocols provided by 
the manufacturer. The antibodies used were a mouse anti-
MLH1 monoclonal antibody (clone ES05; dilution 1:100; 
ZSGB-BIO), a rabbit anti-MSH2 monoclonal antibody 
(clone RED2; dilution 1:150; ZSGB-BIO), a rabbit anti-
MSH6 monoclonal antibody (clone EP49; dilution 1:200; 
ZSGB-BIO), and a rabbit anti-PMS2 monoclonal antibody 
(clone EP51; dilution 1:40; ZSGB-BIO). The tissue 
sections were counterstained with hematoxylin. Nuclear 
immunoreactions in lymphocytes, normal colonic mucosa 
cells or stromal cells within the tissue sections served as 
internal positive controls. As an external positive control, 
normal colon tissue was used. The staining of the sections 
was independently evaluated by two experienced GI 
pathologists (X.J.F, W.Y.T).
Copy number variations (CNVs) analysis
Copy number variations (CNVs) were evaluated 
using the CoNVaDING (Copy Number Variation 
Detection In Next-generation sequencing Gene panels) 
tool for detecting single exon CNVs in targeted NGS 
data [13]. In brief, the pooled raw sequence data were 
first demultiplexed, extracting reads per sample. For each 
sample the sequence data were aligned to the human 
reference genome build 37, as released by the 1000 
Genomes project [42], using BWA [43]. The resulting 
BAM files were utilized for CNV calling and genotyping, 
and post-processing was performed using CoNVaDING 
[13]. This algorithm firstly calculates the average depth 
of coverage for each target, and then selects the control 
samples showing the most similar coverage pattern from a 
set of possible control samples based on the match quality 
control (QC) metric, thereby limiting the sample-to-
sample variation. In order to obtain a CNV call, the depth 
of coverage has to differ significantly from the average of 
two alternative normalizations, using either all (autosomal) 
targets or all targets belonging to the same gene. CNVs 
were called by a logical combination of the different 
ratio score that captures the relative coverage difference 
between samples and controls, and the distribution score 
based on a Z-score calculation, which indicates whether a 
difference is significant or not. QC metrics were calculated 
for the samples and the targets, making explicit which 
targets are suitable for analysis with high sensitivity and 
specificity. Using the target QC values to filter CNVs, high 
quality calls are separated from calls that are more likely 
to be false positives.
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